Rising geopolitical instability is increasingly reframing Serbia’s economic risk profile beyond the usual focus on energy security, bringing into sharper view a less visible but equally strategic vulnerability: the country’s deep reliance on imported pharmaceuticals.
The pharmaceutical sector has become the second-largest component of Serbia’s imports, immediately after oil, with a trade deficit exceeding €1.16 billion. Despite this scale, the issue has remained largely outside public debate, even as global tensions—particularly in the Middle East—raise concerns over supply chains and transport disruptions.
This imbalance is structural rather than cyclical. Serbia imports pharmaceuticals, medical devices, and raw materials at a scale that significantly exceeds domestic production capacity. Annual imports of medicines, medical equipment, and supplements exceed €1.9 billion, while exports reach only about €739.6 million, leaving a persistent and widening deficit.
At the core of this dependency lies the transformation of Serbia’s pharmaceutical industry over the past two decades. The sector, once anchored by large domestic producers such as Galenika and Jugoremedija, has been largely privatized or diminished, with ownership and control shifting toward multinational companies. Economists argue that this process has effectively reduced domestic strategic autonomy in a sector that is both highly profitable and critical for public health.
Today, the domestic production base is fragmented. Although 24 companies in Serbia are involved in some form of pharmaceutical production, only seven facilities carry out the full manufacturing process, while many others focus on packaging or partial processing. This limited industrial depth means that even locally produced medicines often depend heavily on imported active pharmaceutical ingredients and intermediates.
The global structure of pharmaceutical supply chains further amplifies this vulnerability. Over time, the production of key chemical compounds and active ingredients has shifted toward large-scale manufacturing hubs in China, India, and South Korea, creating a concentrated upstream dependency that affects not only Serbia but also major Western markets.
In such a system, geopolitical shocks do not need to directly target pharmaceutical production to trigger disruption. Instead, they operate through indirect channels—primarily energy and logistics. Conflicts that affect oil supply routes or transport corridors can disrupt the movement of raw materials and finished medicines, triggering a “domino effect” across global supply chains.
For Serbia, this linkage is particularly acute. While pharmaceuticals are not directly tied to energy markets, the logistics infrastructure that underpins supply—shipping routes, air freight capacity, and fuel costs—is highly sensitive to geopolitical tensions. A disruption in any of these channels can translate into delayed deliveries, increased costs, or temporary shortages.
Industry experts note that immediate risks remain contained. Pharmaceutical companies typically maintain inventory buffers covering several months of production, and many raw materials are transported by air rather than sea, reducing exposure to maritime disruptions. Moreover, key supply regions are geographically distant from current conflict zones, providing an additional layer of resilience in the short term.
However, the longer-term picture is less stable. Serbia’s pharmaceutical dependency is not only external but also geographically concentrated. The country relies heavily on imports from Hungary, Switzerland, Germany, Slovenia, and France, while exports are distributed across a broader but less economically significant set of markets. This asymmetry reinforces Serbia’s position as a net importer within the European pharmaceutical ecosystem.
The structure of the domestic market further underscores this imbalance. Out of more than 56,000 registered medical products available in Serbia, only about 1,300 are domestically produced, highlighting the limited scope of local manufacturing.
Even in segments where Serbia shows relative strength—such as dietary supplements—the balance is only marginally improved, with imports and exports nearly equal in value. This suggests that the broader pharmaceutical ecosystem remains externally anchored, with limited capacity to substitute imports in a crisis scenario.
The convergence of these factors points to a systemic exposure rather than a temporary imbalance. In a prolonged geopolitical crisis, Serbia could face compounded risks: higher import costs due to energy price spikes, logistical bottlenecks affecting delivery times, and intensified competition for limited global supply—especially if larger markets prioritize domestic needs.
The current environment therefore shifts the policy debate from efficiency toward resilience. While full self-sufficiency in pharmaceuticals is neither feasible nor economically rational for a small market, the erosion of domestic production capacity has narrowed Serbia’s strategic options. Rebuilding selected segments—particularly in generic drug production or critical medical supplies—may become less a question of industrial policy and more one of national security.
What is emerging is a broader redefinition of economic vulnerability. Just as energy security has become central to policy frameworks across Europe, pharmaceutical security is increasingly moving into the same category. For Serbia, the intersection of these two domains—energy and health—creates a compounded exposure that becomes most visible precisely in periods of geopolitical stress.
